J&J Covid-19 vaccine in limbo as US panel delays vote on resuming shots

Johnson & Johnson's COVID-19 vaccine remained in limbo on Wednesday as a U.S. health panel called for more data before making a decision on how and whether to resume use of the one-dose shot, putting off a vote for a week or more.

The U.S. Centers for Disease Control and Prevention (CDC) advisory panel decided to delay a vote on how best to use the J&J shot even after a U.S. Food and Drug Administration scientist told advisers he believed warnings could mitigate the risk of extremely rare but serious blood clots. The panel is reviewing six reported cases of rare brain blood clots in women who received the J&J vaccine, a day after the FDA and CDC jointly recommended pausing its use to assess the issue.